Genzyme licenses Synpac's Pompase

Synpac ( Research Triangle Park, N.C.) granted GENZ exclusive worldwide rights to develop and commercialize Pompase recombinant human alpha-glucosidase as an enzyme replacement therapy for Pompe disease. GENZ and partner Pharming (EASD:PHAR) plan to equally fund the development and commercialization of Pompase. Synpac will receive $19.5 million from GENZ, and PHAR will issue a convertible note to GENZ for $10 million. ...